VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pelvic floor therapy.
- Who it may be relevant to
- Registry conditions: Genito-Pelvic Pain/Penetration Disorder, Dyspareunia, Vaginismus, Pelvic Pain. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
VIBRENT- VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia
Overview
The goal of this randomized controlled trial is to determine whether the use of a novel vibrating pelvic floor therapeutic device ("Kiwi") improves sexual function in sexually active women aged 18 and older with genito-pelvic pain and penetration disorder (GPPPD) more effectively than traditional vaginal dilators. The main questions it aims to answer are: 1. Does the use of the Kiwi device lead to higher sexual function scores compared to traditional vaginal dilators 2. Does the Kiwi device improve sexual distress, pain, and overall symptom severity more effectively than traditional vaginal dilators? Researchers will compare the Kiwi vibrating device to traditional cylindrical vaginal dilators to assess whether the Kiwi device results in greater improvements in sexual function and symptom relief. Participants will: * Be randomly assigned to use either the Kiwi device or traditional vaginal dilators. * Use the assigned device three times per week for 15 minutes per session over four weeks. * Complete surveys before and after the study, including assessments of sexual function, pain, and overall improvement.
Detailed description
This randomized controlled trial (RCT) aims to evaluate the efficacy of a novel vibrating pelvic floor therapeutic device (the "Kiwi") compared to traditional vaginal dilators in improving sexual function outcomes in sexually active women aged 18 and older with genito-pelvic pain and penetration disorder (GPPPD).
The primary objective is to determine whether the Kiwi device leads to higher Female Sexual Function Index (FSFI) scores after four weeks of use compared to traditional dilators.
Secondary objectives include assessing improvements in:
* Sexual distress (Female Sexual Distress Scale - Desire/Arousal/Orgasm, FSDS-DAO) * Pelvic pain (Vulvar Pain Assessment Questionnaire, VPAQ-screen subscale) * Overall symptom severity (Patient Global Impression of Severity, PGI-S) * Perceived improvement (Patient Global Impression of Improvement, PGI-I)
Participants (n=60) will be randomized into two arms:
1. Kiwi device group - a commercially available vibrating pelvic floor therapeutic product. 2. Traditional dilator group - a standard graduated cylindrical vaginal dilator set.
Participants will use their assigned device three times per week for 15 minutes per session over a four-week period. Data will be collected at baseline and at the end of the study using validated questionnaires.
The study hypothesizes that participants using the Kiwi device will demonstrate greater improvements in FSFI scores compared to those using traditional vaginal dilators, reflecting enhanced sexual function and reduced symptom severity.
Interventions
- Device Pelvic floor therapy
Once randomized to either the vibrating pelvic floor massage arm or the traditional vaginal dilator arm, they will receive instructions on frequency of device use and will use manufacturer's instructions for specifics of device use. We will not dictate more specific instructions on use, nor is this standard of care, as every patient is unique and will need to retain autonomy in terms of how quickly they progress in the use of the product. They will then complete a survey at 4 weeks which include
Primary outcome measures
- Female Sexual Function Index (FSFI) [Time frame: Four weeks]
Secondary outcome measures (5)
- FSDS-DAO (Female Sexual Distress Scale- Distress/Arousal/Orgasm) Questionnaire [Time frame: Four weeks]
- Primary Outcome Questionnaire (PEQ) [Time frame: Four weeks]
- PGI-S- Patient Global Impression of Severity [Time frame: Four weeks]
- Patient Global Impression Of Improvement (PGI-I) [Time frame: Four weeks]
- VPAQ-screen Subscale: Self Stimulation/Penetration Interference (Vulvar Pain Assessment Questionnaire- Screening Form) [Time frame: Four weeks]
Eligibility criteria
Inclusion criteria
- Assigned female at birth
- Age ≥ 18 years old
- Genito-pelvic pain/penetration disorder (per ICD-10 diagnosis codes: F52.5 Vaginismus not due to a substance or known physiological condition, F52.6 Dyspareunia not due to a substance or known physiological condition, N94.1 Dyspareunia, N94.2 Vaginismus, N94.81 Vulvodynia)
Exclusion criteria
- Current or prior use of a therapeutic vaginal device used to treat GPPPD
- Unmanaged genitourinary syndrome of menopause
- History of pelvic radiation
- History of genital tract malignancy
- History of female genital mutilation
- History of prior surgery for prolapse or incontinence, including vaginal mesh or midurethral sling mesh
- Silicone allergy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- MedStar Health — Washington D.C.
Identifiers
NCT: NCT06840314 · STUDY00008357